MARKET WIREStocktwits • 17h ago
ENTA: Enanta Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
Why ENTA Stock dropped -3.95% Today — RQD Quant Desk Flash
$10.71 -3.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.61
Enanta Pharmaceuticals Inc. (ENTA) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $311.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ENTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ENTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.71 (-3.95% 1D, market cap $311.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTA ranks #978 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ENTA compare to ARCT and PRLD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ENTA?
▼
Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.61 (-0.90%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENTA)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY ENTA SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (25% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$11.52+1.3% Next Q
28
Q2 (-2Q)Grade E$11.67+4.4% Next Q
25
Q3 (-1Q)Grade E$12.18-12.1% Next Q
23
CurrentGrade E$10.71-11.8% Hist 90D α
20
Trajectory: E (28) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ENTA Turnaround Squeeze
While ENTA currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.42) and Max Pain ($11.25) forces dealer call-delta covering toward $18.01.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ENTA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ENTA Stock dropped -3.95% Today — RQD Quant Desk Flash
Enanta Pharmaceuticals Inc. (ENTA) dropped -3.95% to $10.71, trading at 7% of its 52-week range ($10.22 – $17.15). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($10.22 – $17.15) with RSI-14 at 38.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.5% around $10.71 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ENTA Headlines & Catalysts
MARKET WIREThe Globe and Mail • 20h ago
Enanta Pharmaceuticals Announces CEO Retirement and COO AppointmentThe Globe and Mail report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 23h ago
BlackRock reports a passive stake above 5% in Enanta (ENTA).Stock Titan report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Enanta Pharmaceuticals (ENTA) Ticks Up 0.93% to $12.96 as Shares Sit Mid-Range Between Key Levels - Stock Newshttps://www.siam.in/ report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
A respiratory virus has no approved antiviral. Enanta has begun testing a drug in high-risk adults.Stock Titan report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Enanta announces October 22 RSV data presentation for Enanta Pharmaceuticals stockad-hoc-news.de report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
CATALYSTwww.dars.gov.et • 1d ago
Enanta Pharmaceuticals (ENTA) Gains 2.74% to $11.62 as Buyers Test Resistance - Overbought Signal Alertswww.dars.gov.et report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 4d ago
Enanta Pharmaceuticals Files Patent Infringement Lawsuit Against Pfizer Over Alleged Infringement Of European Patent Regarding Pfizer's Manufacture, Use, And Sale Of Paxlovidhttps://www.sec.gov/ix?doc=/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
RISK WATCHYahoo • 5d ago
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company LeadershipWATERTOWN, Mass., October 28, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces
MARKET WIREYahoo • 7d ago
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)WATERTOWN, Mass., October 26, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today ann
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENTA)
- ✓Walkthrough of ENTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ENTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.34%🛡️ HOLDING TREND SUPPORT
2026-11-03O $11.15H $11.15L $10.71C $10.71VOL 202.3K
RES: $14.44SUP: $10.64SMA50: $12.42SMA200: $13.17
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ENTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ENTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ENTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENTA)
Health Care Rank #978 of 1016
⚔️ ARCT vs ENTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ENTA vs. ARCT, PRLD, TTRX, IRD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Enanta Pharmaceuticals Inc. (ENTA) ranks #978 by composite RQD confidence (20/100, grade E) and #511 by equity capitalization ($311.9M). Within this direct 5-issuer industry benchmark cohort, ENTA leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. TTRX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ENTA at 20/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENTA
ACTIVE
Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.95% | $311.9M | Benchmark Subject |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 25/100 | — | — | -35.0% | -9.22% | $313.5M | /arct-vs-enta → |
| PRLD Prelude Therapeutics Incorporated | E | 33/100 | — | — | -35.0% | -5.37% | $309.6M | /prld-vs-enta → |
| TTRX Turn Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -2.70% | $318.5M | /ttrx-vs-enta → |
| IRD Opus Genetics Inc. | E | 23/100 | — | — | -35.0% | +0.55% | $305.3M | /ird-vs-enta → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001177648In its most recent audited fiscal period (FY2025, filed 2025-09-30), Enanta Pharmaceuticals Inc. (ENTA) reported GAAP revenue of $65.3M (-3.4% vs. FY2024 revenue of $67.6M , and -17.5% cumulative change since FY2023) , GAAP net income of -$81.9M, operating cash flow of -$19.3M, and free cash flow of -$32.2M (+66.7% YoY). On the balance sheet, ENTA closed FY2025 with $329.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $65.3M | -$81.9M | -$19.3M | -$32.2M | $329.5M | — |
| FY2024 (FY) | 2024-09-30 | $67.6M | -$116.0M | -$78.8M | -$96.7M | $348.6M | — |
| FY2023 (FY) | 2023-09-30 | $79.2M | -$133.8M | -$103.2M | -$103.2M | — | — |
3. ENTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ENTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.71 (-3.95% 1D, market cap $311.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTA ranks #978 in composite RQD confidence.
How does ENTA compare to ARCT and PRLD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ENTA?
Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ENTA trading relative to its 50-day, 200-day, and 52-week technical levels?
ENTA last traded at $10.71 (-3.95% on volume of 202,346 shares), positioning the stock -13.77% below its 50-day simple moving average ($12.42) and -18.68% below its 200-day simple moving average ($13.17). Across its 52-week range of $10.22 to $17.15, ENTA sits at the 7.1% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($9.48 to $11.94).
ENTA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ENTA stock moving today?
Why ENTA Stock dropped -3.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 20/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ENTA — Enanta Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:27Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ENTA scores 20 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -9.91%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5).
For a prospective investor, the pattern is weak across every pillar. The cash engine pillar reflects negative return on invested capital and negative free cash flow yield, meaning the business is consuming rather than generating cash relative to its market value. The forensic pillar reflects an Altman Z-Score of 0.2 and a Piotroski F-Score of 3 out of 9, both of which point to elevated financial distress risk and weak fundamental health. The smart money pillars score low, and the sole sourced institutional item is a BlackRock passive stake above 5%, which is a passive index-style position rather than evidence of active conviction. Upside drivers in the source data are limited to the possibility that pipeline news (the RSV data presentation and antiviral testing headlines) could re-rate the stock; the source data does not quantify that outcome. Valuation tradeoffs are significant: with negative earnings and free cash flow, traditional earnings multiples are unavailable, and the market capitalization of $324.7M sits against cumulative losses shown in the financials. The verdict is a risk-assessment signal, not a recommendation.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $65.3M | $-85.3M | $-81.9M | N/A | $-32.2M | $37.4M | N/A |
| FY 2024 | $67.6M | $-121.7M | $-116.0M | N/A | $-96.7M | $84.3M | N/A |
| FY 2023 | $79.2M | $-137.2M | $-133.8M | N/A | $-103.2M | N/A | N/A |
Per the SEC financials, revenue declined from $79.2M (FY 2023) to $65.3M (FY 2025) while net losses narrowed from $-133.8M to $-81.9M. Per the market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5, indicating a weak balance-sheet posture. Reported cash declined from $84.3M (FY 2024) to $37.4M (FY 2025).
Recent Catalysts & News Wire Analysis
- Stocktwits report (YELLOW, Market Wire): General market-action and positioning coverage.
- CEO retirement and COO appointment (YELLOW, Market Wire): Leadership transition announced per The Globe and Mail.
- BlackRock passive stake above 5% (YELLOW, Market Wire): Reported via Stock Titan.
- Price-action note (YELLOW, Market Wire): Coverage of the stock trading mid-range between key levels.
- Respiratory antiviral testing in high-risk adults (RED, Risk Watch): Per Stock Titan, Enanta has begun testing a drug where no approved antiviral exists; flagged as a risk-watch item.
- October 22 RSV data presentation (YELLOW, Market Wire): Per ad-hoc-news.de, a scheduled data presentation.
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the specific products, customers, and revenue model that generated the reported FY 2025 revenue of $65.3M?
- What is the cash runway given reported cash of $37.4M and FY 2025 free cash flow of $-32.2M?
- What is the outcome of the October 22 RSV data presentation and the respiratory antiviral trial?
- What is the debt position, since FY debt is reported as N/A across all periods?
- What are the terms and timing of the CEO retirement and COO appointment, and how might they affect execution?
ENTA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Enanta Pharmaceuticals Inc. (ENTA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 17h ago
ENTA: Enanta Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 20h ago
Enanta Pharmaceuticals Announces CEO Retirement and COO Appointment The Globe and Mail report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
BlackRock reports a passive stake above 5% in Enanta (ENTA). Stock Titan report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Enanta Pharmaceuticals (ENTA) Ticks Up 0.93% to $12.96 as Shares Sit Mid-Range Between Key Levels - Stock News https://www.siam.in/ report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
A respiratory virus has no approved antiviral. Enanta has begun testing a drug in high-risk adults. Stock Titan report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Enanta announces October 22 RSV data presentation for Enanta Pharmaceuticals stock ad-hoc-news.de report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.dars.gov.et • 1d ago
Enanta Pharmaceuticals (ENTA) Gains 2.74% to $11.62 as Buyers Test Resistance - Overbought Signal Alerts www.dars.gov.et report covering Enanta Pharmaceuticals Inc. (ENTA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 4d ago
Enanta Pharmaceuticals Files Patent Infringement Lawsuit Against Pfizer Over Alleged Infringement Of European Patent Regarding Pfizer's Manufacture, Use, And Sale Of Paxlovid https://www.sec.gov/ix?doc=/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ENTA Bull vs. Bear Conversation Board — What's Your Call at $10.71?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENTA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $9.81 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ENTA (E • RQD 20/100) a Buy at $11.15?
Welcome to the ENTA (Enanta Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 20/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $8.92 (-20.0%)
Spot @ $11.15 Pump the brakes on ENTA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ENTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Enanta Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $14.27 (+28.0%)
Spot @ $11.15 ENTA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ENTA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.15 (52-wk range $10.22 - $17.15), any beat on forward guidance forces shorts and underweight funds to chase.